Life Sciences

  • March 27, 2026

    Biogen Beats Investor Suit Over Dozens Of Drug Claims

    Biogen Inc. and four of its executives escaped a stock drop suit Friday after a Massachusetts federal judge ruled that none of the nearly five dozen statements challenged by investors suggested that the company intentionally misled people buying its stock.

  • March 27, 2026

    Mississippi Gov. Vetoes Medical Marijuana Expansion Bill

    Mississippi Gov. Tate Reeves has vetoed a bill to expand the state's medical cannabis program to include severely ill patients, while approving another bill to fund a clinical trial into the psychedelic ibogaine.

  • March 27, 2026

    NJ Federal Judge DQs Beasley Allen In J&J Talc MDL

    A New Jersey federal judge has disqualified the Beasley Allen Law Firm from representing hundreds of plaintiffs in sprawling multidistrict litigation over Johnson & Johnson's talc-based baby powder, holding that the firm violated ethics rules by collaborating with former outside counsel for J&J, a ruling the law firm has vowed to appeal.

  • March 27, 2026

    Pharma Co. Says Exec Was Fired Over Conduct, Not Piglets

    The U.S. arm of a Danish pharmaceutical company has told a North Carolina federal judge to throw out a former director's "extraordinary and conspiratorial" lawsuit claiming he was fired for expressing concerns about his employer's use of piglets at an anniversary party.

  • March 27, 2026

    Kirkland-Led Transcend Bought By Otsuka In $1.2B Deal

    Clinical-stage biotechnology company Transcend Therapeutics Inc., led by Kirkland & Ellis LLP, Pillsbury Winthrop Shaw Pittman LLP and Goodwin Procter LLP, on Friday announced that it has agreed to be bought by Otsuka Pharmaceutical Co. Ltd. in a deal worth up to $1.225 billion.

  • March 26, 2026

    Elanco Beats Investor Suit Over Dog Drug's Reg Challenges

    A Maryland federal judge Thursday dismissed a proposed securities class action against Elanco Animal Health Inc. that claimed the animal pharmaceuticals company misled investors about the safety of a canine dermatitis treatment it was developing and its timeline for the medication's commercial launch.

  • March 26, 2026

    Fed. Circ. Rejects Pharma Co. Refiling Suit To Reset Deadline

    Ascendis Pharma missed its window to invoke a mandatory stay in California federal court based on parallel U.S. International Trade Commission proceedings, and its attempt to reset the patent litigation doesn't change that, the Federal Circuit said Thursday.

  • March 26, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Lawmakers at the state and federal level stewarded legislation to rein in kratom and its derivatives, Idaho lawmakers took a stand against a proposal to legalize medical marijuana via ballot initiative, and New York legislators introduced a plan to audit the state's cannabis regulator on an annual basis. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • March 26, 2026

    McDonald Hopkins Must Produce Fraud Warning Docs

    Midwestern law firm McDonald Hopkins LLC must produce email communications in connection with litigation accusing Blue Cross units of a smear campaign against a clinical lab owner, an Ohio federal judge ruled, finding the documents were not protected by work product or attorney-client privilege.

  • March 26, 2026

    Abbott Unit Beats Ex-Worker's Whistleblower Suit At 8th Circ.

    The Eighth Circuit declined Thursday to reinstate a former worker's suit claiming he was fired from an Abbott Laboratories subsidiary for reporting healthcare kickback violations, ruling he couldn't sue under the Minnesota whistleblower law as a Hawaii resident.

  • March 26, 2026

    Pa. Justices Deem Pot Group Unharmed By Abstinence Rule

    The Pennsylvania Supreme Court on Thursday held that a cannabis trade association lacks standing to argue that a local court's policy of regulating medical marijuana use for treatment court participants hurts dispensary businesses, upholding a ruling that the association didn't suffer any harm itself from the policy.

  • March 26, 2026

    9th Circ. Upholds Medtronic Win In Spinal Cord Device Suit

    A Washington man cannot sue medical device maker Medtronic USA Inc. on allegations it sold him a spinal cord implant that malfunctioned causing greater pain, the Ninth Circuit ruled, saying he lacked expert witnesses to support his negligence claims.

  • March 26, 2026

    Regeneron Can't Sink Disability Bias Claims Over Scheduling

    A former Regeneron Pharmaceuticals director can proceed with her lawsuit claiming she was fired for requesting a flexible schedule to care for her daughter, a New York federal judge ruled, saying she'd sufficiently backed up allegations that doing so had violated federal disability bias law.

  • March 25, 2026

    PTAB Was Never '100% Discretionary,' Rep. Issa Tells Squires

    U.S. Patent and Trademark Office Director John Squires is exceeding the authority Congress intended to grant him in the America Invents Act for discretionarily denying patent challenges, the U.S. House of Representatives' intellectual property leader said Wednesday.

  • March 25, 2026

    AbbVie, Novartis Sue Wash. Over New 340B Drug-Pricing Law

    Pharmaceutical giants Novartis and AbbVie say a new Washington state law illegally expands drugmakers' obligations to provide deeply discounted medications under the federal government's 340B Drug Pricing Program, according to a pair of legal challenges launched in federal court on Wednesday.

  • March 25, 2026

    Ex-Pharma GC Freed From Trade Secrets Suit Amid Ch. 7 Stay

    A Texas federal judge agreed to dismiss claims against the ex-general counsel of a Houston-based pharmaceutical services company, who was accused of helping build a competing venture using confidential information and of destroying a hard drive containing evidence he had a duty to preserve during litigation.

  • March 25, 2026

    Co.'s Dual Citizenship Doesn't Kill Jurisdiction, 4th Circ. Told

    A medical supply company urged the Fourth Circuit on Wednesday to revive its suit against a U.K. company over COVID-19 test kits, arguing the Chinese citizenship of one of its members doesn't destroy a North Carolina federal judge's ability to hear the case.

  • March 25, 2026

    Mom Tying Abbott Formula To Baby's NEC Takes The Stand

    A plaintiff claiming Abbott Laboratories' preterm baby formula contributed to her infant's development of a serious gut condition told an Illinois jury Wednesday that she wouldn't have allowed her baby to consume the formula had she known it increased the risk of the infection, saying her now-teenage daughter still struggles with medical complications as a result.

  • March 25, 2026

    Fecal Treatment Co. Says Ch. 11 Is Best Option To Sell Assets

    Microbiome treatment developer Finch Therapeutics told a Delaware bankruptcy judge Wednesday that its lack of income or ability to collect on a patent judgment justified its Chapter 11 filing despite a lack of secured debts.

  • March 25, 2026

    Judge Trims SEC Fraud Case Over Cancer Drug Claims

    A Massachusetts federal judge greenlighted U.S. Securities and Exchange Commission claims against two of three former pharmaceutical executives accused of concealing from investors the U.S. Food and Drug Administration's "harsh critiques" about a cancer drug.

  • March 25, 2026

    Insurer Need Not Cover Parkinson's Drug Antitrust Dispute

    An insurer does not owe coverage in an antitrust suit accusing a pharmaceutical company of suppressing generic versions of the Parkinson's treatment Apokyn, a Maryland federal judge ruled, finding the dispute does not involve "securities claims" covered under the insurer's policy.

  • March 25, 2026

    Biotech 'Lowballed' Landlord On Lease Exit, Suit Says

    Biopharma company Werewolf Therapeutics has offered its Massachusetts landlord little more than 10 cents on the dollar to buy out the remainder of a lease for its lab space, even as the firm pays out departing executives and other creditors, according to a lawsuit brought in state court.

  • March 25, 2026

    Dechert Adds Paul Weiss Patent Partners In DC, NY

    Dechert LLP has hired two Paul Weiss Rifkind Wharton & Garrison LLP lawyers who have backgrounds in life sciences and electrical engineering, the firm announced Tuesday.

  • March 25, 2026

    Covington, Freshfields Advise On $6.7B Merck Oncology Deal

    Merck & Co. said Wednesday it will acquire clinical-stage oncology company Terns Pharmaceuticals Inc. for $53 per share in cash, giving the deal an equity value of $6.7 billion.

  • March 24, 2026

    Trump Admin Settles Suit Over Biden Social Media Collabs

    The Trump administration on Tuesday agreed to bar three federal agencies from interfering with social media companies' content moderation, resolving a high-profile challenge to the Biden administration's efforts to combat the spread of misinformation in a case that went up to the U.S. Supreme Court.

Expert Analysis

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.